The DOI matches its Crossref record.
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours
Open accessAbstract
Circulating neuron-specific enolase (NSE) and chromogranin A (CgA) were measured in 128 patients with neuroendocrine tumours (NET) to compare their sensitivity and specificity, to investigate factors associated with elevated serum levels and to determine the usefulness of these markers in the follow-up of NET patients. NSE (Cispack NSE, Cis Bio International, Gif-sur-Yvette, France; normal <12.5 microg l(-1)), and chromogranin A (CgA-Riact, Cis Bio International, normal <100 microg l(-1)) were measured in 128 patients without renal insufficiency. There were 99 patients with gastroenteropancreatic (GEP) NET, 19 with medullary thyroid carcinoma and ten with phaeochromocytoma. Fifty-three patients with non-NET were studied as controls. Serum NSE and CgA levels were elevated in 48 (38%) and 76 (59%) of the 128 NET patients respectively. In all groups of NET patients, CgA proved to be more sensitive than NSE. NSE and CgA had a specificity of 73% and 68% respectively. Immunostaining for NSE was positive in three out of eight controls with elevated CgA levels, whereas immunostaining for CgA and synaptophysin was negative in all cases. Elevated CgA levels were significantly associated with two independent parameters, namely the presence of other secretions (P = 0.0001) and a heavy tumour burden (P = 0.001). Elevated NSE levels were exclusively associated with poor tumour differentiation (P = 0.01). Among six patients with NET followed for 11-37 months, CgA appeared to be a better marker of tumour evolution than NSE. We suggest that CgA ought to be the only general marker screened in NET patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., Oberg, K., Pelosi, G., Perren, A., Rossi, R. E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv041 · Cited by 714
Self-citationThe diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Garcia-Carbonero, R., Sorbye, H., Baudin, E., Raymond, E., Wiedenmann, B., Niederle, B., Sedlackova, E., Toumpanakis, C., Anlauf, M., Cwikla, J. B., et al. (2016) · Neuroendocrinology · doi:10.1159/000443172 · Cited by 611
Self-citationNeuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects
Isgrò, M. A., Bottoni, P., & Scatena, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_9 · Cited by 575
Falconi, M., Bartsch, D. K., Eriksson, B., Klöppel, G., Lopes, J. M., O'Connor, J. M., Salazar, R., Taal, B. G., Vullierme, M. P., & O'Toole, D. (2012) · Neuroendocrinology · doi:10.1159/000335587 · Cited by 526
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
Mitry, E., Baudin, E., Ducreux, M., Sabourin, J.-C., Rufié, P., Aparicio, T., Lasser, P., Elias, D., Duvillard, P., Schlumberger, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690325 · Cited by 496
Self-citationNasrullah, N., Sang, J., Alam, M. S., Mateen, M., Cai, B., & Hu, H. (2019) · Sensors · doi:10.3390/s19173722 · Cited by 359
Gastroenteropancreatic high‐grade neuroendocrine carcinoma
Sorbye, H., Strosberg, J., Baudin, E., Klimstra, D. S., & Yao, J. C. (2014) · Cancer · doi:10.1002/cncr.28721 · Cited by 347
Self-citationAre G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise, F.-L., Duvillard, P., Foucan, L., Hadoux, J., Chougnet, C. N., Leboulleux, S., Malka, D., Guigay, J., Goere, D., Debaere, T., et al. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0027 · Cited by 325
Self-citationENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
O’Toole, D., Grossman, A., Gross, D., Delle Fave, G., Barkmanova, J., O’Connor, J., Pape, U.-F., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225948 · Cited by 268
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177
“Regarding the metastatic status, it has been suggested that CgA level is a reflection of tumour spreading with the highest levels when liver metastases had developed (Baudin et al., 1998; Tomassetti et al., 2001).”
BackgroundResultKnigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen van Dijkum, E., O'Toole, D., et al. (2017) · Neuroendocrinology · doi:10.1159/000458155 · Cited by 136
Korse, C. M., Bonfrer, J. M. G., Aaronson, N. K., Hart, A. A. M., & Taal, B. G. (2009) · Neuroendocrinology · doi:10.1159/000162876 · Cited by 61
RELATIONSHIP BETWEEN RENAL FUNCTION AND BLOOD LEVEL OF CHROMOGRANIN A
Tramonti, G., Ferdeghini, M., Annichiarico, C., Norpoth, M., Donadio, C., Bianchi, R., & Bianchi, C. (2001) · Renal Failure · doi:10.1081/jdi-100104728 · Cited by 48
Vezzosi, D., Walter, T., Laplanche, A., Raoul, J. L., Dromain, C., Ruszniewski, P., d'Herbomez, M., Guigay, J., Mitry, E., Cadiot, G., et al. (2011) · The International Journal of Biological Markers · doi:10.5301/jbm.2011.8327 · Cited by 43
Self-citationJilesen, A. P. J., Busch, O. R. C., van Gulik, T. M., Gouma, D. J., & Nieveen van Dijkum, E. J. M. (2014) · Digestive Surgery · doi:10.1159/000370007 · Cited by 26
Metadata
- Authors
- Baudin, E., Gigliotti, A., Ducreux, M., Ropers, J., Comoy, E., Sabourin, J., Bidart, J., Cailleux, A., Bonacci, R., Ruffié, P., & Schlumberger, M.
- Venue
- British Journal of Cancer
- Published
- 1998-10
- Volume
- 78
- Issue
- 8
- Pages
- 1102-1107
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2031612391
- Cited by
- 250
- References
- 0
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.